Peringatan Keamanan

The most common side effects that occurred during siltuximab treatment were pruritis, increased weight, rash, hyperuricemia, and upper respiratory tract infection. Siltuximab should not be administered to patients with severe infections as it may mask signs and symptoms of acute inflammation including suppression of fever and acute phase reactants such as C-reactive protein (CRP). Gastrointestinal perforation has been reported in clinical trials, therefore use with caution in patients who may be at increased risk for GI perforation.

Siltuximab

DB09036

biotech approved investigational

Deskripsi

Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal half life after the first intravenous infusion of 11 mg/kg is 20.6 days.
Volume Distribusi Based on population pharmacokinetic analysis, the central volume of distribution in a male subject with body weight of 70 kg is 4.5 L.
Klirens (Clearance) Body weight was identified as the only statistically significant covariate of siltuximab clearance, therefore body weight based dosing is appropriate. Based on population pharmacokinetic analysis, the clearance of situximab in patients is 0.23 L/day.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

As siltuximab is an antibody, the expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1408 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Siltuximab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Siltuximab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siltuximab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Siltuximab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Siltuximab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Siltuximab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Siltuximab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Siltuximab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Siltuximab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Siltuximab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Siltuximab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siltuximab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Siltuximab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siltuximab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siltuximab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Siltuximab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Siltuximab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Siltuximab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Siltuximab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siltuximab.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Siltuximab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Siltuximab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siltuximab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siltuximab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Siltuximab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Siltuximab.
Cladribine Siltuximab may increase the immunosuppressive activities of Cladribine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Siltuximab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Siltuximab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Siltuximab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Siltuximab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Siltuximab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Siltuximab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Siltuximab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siltuximab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Siltuximab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Siltuximab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Siltuximab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Siltuximab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Siltuximab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Siltuximab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Siltuximab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Siltuximab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siltuximab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Siltuximab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Siltuximab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Siltuximab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Siltuximab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Siltuximab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Siltuximab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Siltuximab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Siltuximab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Siltuximab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Siltuximab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Siltuximab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Siltuximab.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Siltuximab.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Siltuximab.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Siltuximab.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Siltuximab.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Siltuximab.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Siltuximab.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Siltuximab.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Siltuximab.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Siltuximab.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Siltuximab.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Siltuximab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Siltuximab.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Siltuximab.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Siltuximab.
Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Siltuximab.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Siltuximab.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Siltuximab.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Siltuximab.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Siltuximab.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Siltuximab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Siltuximab.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Siltuximab.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Siltuximab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Siltuximab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Siltuximab.
Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Siltuximab.
Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Siltuximab.
Rilonacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Siltuximab.
Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Siltuximab.
Abetimus The risk or severity of adverse effects can be increased when Abetimus is combined with Siltuximab.
Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Siltuximab.
Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Siltuximab.
Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Siltuximab.
Wortmannin The risk or severity of adverse effects can be increased when Wortmannin is combined with Siltuximab.
Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Siltuximab.
Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Siltuximab.
Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Siltuximab.
Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Siltuximab.
Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Siltuximab.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Siltuximab.
Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Siltuximab.
Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Siltuximab.

Target Protein

Interleukin-6 IL6

Referensi & Sumber

Artikel (PubMed)
  • PMID: 20179212
    Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM: Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010 Mar 1;16(5):1652-61. doi: 10.1158/1078-0432.CCR-09-2581. Epub 2010 Feb 23.
  • PMID: 25601959
    Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J, Mehrotra N, Del Valle P, Saber H, Sheth C, Gehrke B, Justice R, Farrell A, Pazdur R: FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015 Mar 1;21(5):950-4. doi: 10.1158/1078-0432.CCR-14-1678. Epub 2015 Jan 19.
  • PMID: 25110138
    Liu YC, Stone K, van Rhee F: Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Sylvant
    Injection, powder, lyophilized, for solution • 100 mg/1 • Intravenous • US • Approved
  • Sylvant
    Injection, powder, lyophilized, for solution • 400 mg/1 • Intravenous • US • Approved
  • Sylvant
    Injection, powder, for solution • 100 mg/1 • Intravenous • US • Approved
  • Sylvant
    Injection, powder, for solution • 400 mg/1 • Intravenous • US • Approved
  • Sylvant
    Powder, for solution • 400 mg / vial • Intravenous • Canada • Approved
  • Sylvant
    Powder, for solution • 100 mg / vial • Intravenous • Canada • Approved
  • Sylvant
    Injection, powder, for solution • 100 mg • Intravenous • EU • Approved
  • Sylvant
    Injection, powder, for solution • 400 mg • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul